Current status of CD4-based therapies for prophylaxis and treatment of HIV infection

BioDrugs

Volumn 8, Issue 2, 1997, Pages 128-138

  Sinclair, Jan P ^a   Shearer, William T ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD4 IMMUNOGLOBULIN; SOLUBLE CD4 ANTIGEN;

CELL MEDIATED CYTOTOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0030748472     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199708020-00006     Document Type: Review

References (61)

1. Smith DH, Bryn RA, Marsters SA, et al. Blocking of HIV-1 infectivity by a soluble secreted form of the CD4 antigen. Science 1987 Dec; 238: 1704-7
2. Deen KC, McDougal JS, Inacker R, et al. A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988 Jan; 331: 82-4
3. Trunecker A, Luke W, Karjalainen K. Soluble CD4 molecules neutralise human immunodeficiency virus type 1. Nature 1988 Jan; 331: 84-6
4. Fisher RA, Bertonis JM, Meier W, et al. HIV infection is blocked in vitro by recombinant soluble CD4. Nature 1988 Jan; 331: 76-8
5. Hussey RE, Richardson NE, Kowalski M, et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988 Jan; 331: 87-91
6. Moore JP, McKeating JA, Weiss RA, et al. Dissociation of gp120 from HIV-1 virons induced by soluble CD4. Science 1990 Nov; 250: 1139-42
7. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: functional cDNA cloning of a seven transmembrane G protein-coupled receptor. Science 1996 May; 272: 872-7
8. Deng H, Liu R, Ellmeir W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996; 381: 661-6
9. Choe H, Farzan M, Sun Y, et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-48
10. Alkhatib G, Combadiere C, Broder C, et al. ce CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-trophic HIV-1. Science 1996; 272: 1955-8
11. Doranz B, Rucker J, Yi Y, et al. A dual-trophic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85: 1149-58
12. Dragic T, Litwin V, Allaway G, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73
13. Moore JP, McKeating JA, Norton WA, et al. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virons: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralisation by soluble CD4. J Virol 1991 Mar; 65 (3): 1133-40
14. Gomatos PJ, Stamatos NM, Gendelman HE, et al. Relative inefficiency of soluble recombinant CD4 for inhibition of infection by monocyte-trophic HIV in monocytes and T cells. J Immunol 1990 Jun; 144 (11): 4183-8
15. Watanabe M, Reimann KA, DeLong PA, et al. Effect of recombinant soluble CD4 in Rhesus monkeys infected with simian immunodeficiency virus of macaques. Nature 1989 Jan; 337: 267-70
16. Kahn JO, Allan JD, Hodges TL, et al. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS related complex. Ann Intern Med 1990 Feb; 112 (4): 254-61
17. Schooley RT, Merigan TC, Gaut P, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1990 Feb; 112 (4): 247-53
18. Daar ES, Li XL, Moudgil T, et al. High concentrations of recombinant soluble CD4 are required to neutralise primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA 1990 Sept; 87: 6574-8
19. Ashkenazi A, Smith DH, Marsters SA, et al. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. Proc Natl Acad Sci USA 1991 Aug; 88: 7056-60
20. Brighty DW, Rosenburg M, Chen ISY, et al. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralisation by soluble CD4 possess high affinity for the CD4 receptor. Proc Natl Acad Sci USA 1991 Sep; 88: 7802-5
21. Moore JP, McKeating JA, Huang Y, et al. Virons of human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralisation differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 1992 Jan; 66 (1): 235-43
22. Sato H, Orenstein J, Dimitrov D, et al. Cell-to-cell spread of HIV-1 occurs within minutes and may not involve the participation of virus particles. Virology 1992; 186: 721-4
23. Gupta P, Balachandran R, Ho M, et al. Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody. J Virol 1989 May; 63 (5): 2361-5
24. Phillips DM. The role of cell-to-cell transmission in HIV infection. AIDS 1994; 8: 719-31
25. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993 Mar; 362: 355-8
26. Schacker T, Coombs RW, Collier AC, et al. The effects of high dose recombinant soluble CD4 on human immunodeficiency virus type 1 viraemia. J Infect Dis 1994 Jan; 169: 37-40
27. Capon DJ, Chamow SM, Mordenti J, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989 Feb; 337: 525-31
28. Traunecker A, Schneider J, Kiefer H, et al. Highly efficient neutralisation of HIV with recombinant CD4-immunoglobulin molecules. Nature 1989 May; 339: 68-70
29. Byrn RA, Mordenti J, Lucas C, et al. Biological properties of a CD4 immunoadhesin. Nature 1990 Apr; 344: 667-70
30. Spear GT, Ghassemi M, Takefman DM. HIV-1 strain dependence of complement-mediated virolysis induced by recombinant CD4-IgG [letter]. J Acquir Immune Defic Syndr 1994; 7: 100-1
31. Allaway GP, Davis-Bruno KL, Beaudry GA, et al. Expression and characterisation of CD4-IgG2, a novel heteroletramer that neutralises primary HIV type 1 isolates. AIDS Res Hum Retrovir 1995; 11: 533-9
32. Gauduin M, Allaway GP, Maddon PJ, et al. Effective ex vivo neutralisation of plasma HIV-1 by recombinant immunoglobulin molecules. J Virol 1996; 70: 2586-92
33. Davey R, Davey V, Polis M, et al. A phase I trial of recombinant human CD4-immunoglobulin(rCD4-IgG) in HIV-1 infection [abstract no. SB481]. Proc VIth International Conference on AIDS; 1990 Jun; San Francisco: 206
34. Hodges TL, Kahn JO, Kaplan LD, et al. Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex. Antimicrob Agents Chemother 1991 Dec; 35 (12): 2580-6
35. Collier AC, Coombs RW, Katzenstein D, et al. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 (2): 150-6
36. Yarchoan Y, Plauda JM, Adamo D, et al. Phase 1 study of rCD4-IgG administered by continuous intravenous (IV) infusion to patients with AIDS or ARC [abstract no. SB479]. Proc VIth International Conference on AIDS; 1990 June; San Francisco: 205
37. Mulligan M, Duliege A, Nail C, et al. HIV-1 therapy with high dose CD4-IgG [abstract no. 2007]. Proc IXth International Conference on AIDS; 1993 Jun 6-11; Berlin
38. Clerici M, Yarchoan R, Blatt S, et al. Effect of a recombinant CD4-IgG on in vitro T helper cell function: data from a phase I/II study of patients with AIDS. J Infect Dis 1993 Oct; 168: 1012-6
39. Roilides E, Clerici M, DePalma L, et al. Helper T cell responses in children infected with human immunodeficiency virus type I. J Pediatr 1991; 118: 724-30
40. Lucey DR, Melcher GP, Hendrix CW, et al. Human immunodeficiency virus infection in the US Air Force: seroconversions, clinical staging, and assessment of T helper functional assay to predict change in CD4+ T cell counts. J Infect Dis 1991; 164: 631-7
41. Tokars JI, Marcus R, Culver DH, et al. CDC Cooperative Needlestick Surveillance Group: surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993; 118: 913-9
42. Gerberding JL. Managing occupational exposures to HIV. In: Broder S, Merigan TC, Bolognesi D, editors. Textbook of AIDS medicine. Baltimore: Williams & Wilkins, 1994: 841-3
43. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994 Nov; 331 (18): 1173-80
44. Ward RHR, Capon DJ, Jett CM, et al. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesion. Nature 1991 Aug; 352: 434-6
45. Shearer WT, Duliege AM, Kline MK, et al. Transport of recombinant CD4-immunoglobulin G across the human placenta: pharmacokinetics and safety in six mother-infant pairs in AIDS Clinical Trial Group Protocol 146. Clin Lab Diag Immunol 1995 May; 2 (3): 281-5
46. Johnson VA, Barlow BD, Chou T, et al. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by recombinant soluble CD4 and 3′-azido-3′-deoxythymidine. J Infect Dis 1989 May; 159 (5): 837-44
47. Johnson VA, Barlow BD, Merrill DP, et al. Three drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J Infect Dis 1990 June; 161: 1059-67
48. Koup RA, Brewster F, Grob P. Nevaripine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesion. AIDS 1993; 7 (9): 1181-4
49. Ushijima H, Kunisada T, Kitamura T, et al. Synergistic effect of recombinant CD4-immunoglobulin in combination with azidothymidine, dideoxyinosine, and 0.5β monoclonal antibody on human immunodeficiency virus infection in vitro. Lett Appl Microbiol 1994; 19: 1-5
50. Meng TC, Fischl MA, Cheeseman SH, et al. Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8 (2): 152-60
51. Kennedy MS, Orloff S, Ibegbu CC, et al. Analysis of synergism/antagonism between HIV-1 antibody positive human sera and soluble CD4 in blocking HIV-1 binding and infectivity. AIDS Res Hum Retrovir 1991; 7 (12): 975-81
52. McKeating J A, Cordell J, Dean CJ, et al. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp 120. Virology 1992; 191: 732-42
53. Allaway GP, Ryder AM, Beaudry GA, et al. Synergistic inhibition of HIV-1 envelope mediated cell fusion by CD4 based molecules in combination with antibodies to gp120 or gp41. AIDS Res Hum Retrovir 1993; 9 (7): 581-7
54. Chaudhary VK, Mizukami T, Fuerst TR, et al. Selective killing of HIV-1 infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 1988 Sept; 335: 369-72
55. Berger EA, Clouse KA, Chaudhary VK, et al. CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses. Proc Natl Acad Sci USA 1989 Dec; 86: 9539-43
56. Ashorn P, Moss B, Weinstein JN, et al. Elimination of infectious human immunodeficiency virus from human T-cell culture by synergistic action of CD4-Psseudomonas exotoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1990 Nov; 87: 8889-93
57. Berger EA, Chaudhary VK, Clouse KA, et al. Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II dependent functions. AIDS Res Hum Retrovir 1990; 6 (6): 795-804
58. Ramachandran R, Katzenstein DA, Wood R, et al. Failure of short term CD4-PE40 infusion to reduce virus load in human immunodeficiency virus infected persons. J Infect Dis 1994 Oct; 170: 1009-13
59. Flasher D, Konopka K, Chamow SM, et al. Liposome targeting to human immunodeficiency virus type 1 infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG). Biochim Biophys Acta 1994; 1194: 185-96
60. NIH AIDS Clinical Trial Group. Concept sheet for study #351: a phase I/II trial of CD4-IgG2 in HIV-viremic children
61. Mofenson LM, Wolinsky SM. Current insights regarding vertical transmission. In Pizzo PA, Wilfert CM, editors. Pediatric AIDS: the challenge of HIV infection in infants, children and adolescents. 2nd ed. Baltimore: Williams & Wilkins, 1994: 179-203